Data / Drug companies / Adapalene and benzoyl peroxide
Adapalene and benzoyl peroxide: 11 companies and 15 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Adapalene and benzoyl peroxide is listed in the FDA National Drug Code Directory by 11 companies, with 15 products in commercial distribution. 13 of the products (86.7%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are gel, and the newest product started marketing on July 22, 2026.
The request: Get every company that lists adapalene and benzoyl peroxide in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 11
- Products
- 15
- Generic (ANDA) products
- 13 (86.7%)
- Application numbers
- 10
- Routes
- Topical
- Brand names
- Differin Epiduo
- openFDA record search
- api.fda.gov
Companies that list adapalene and benzoyl peroxide
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Bryant Ranch Prepack | 2 | gel | Generic drugs (ANDA) | June 2, 2022 |
| Bryant Ranch Prepack | 2 | gel | Generic drugs (ANDA) | June 2, 2022 |
| Padagis Israel Pharmaceuticals Ltd | 2 | gel | Generic drugs (ANDA) | June 2, 2022 |
| Sun Pharmaceutical Industries, Inc. | 2 | gel | Generic drugs (ANDA) | October 17, 2018 |
| Aurobindo Pharma Limited | 1 | gel | Generic drugs (ANDA) | July 22, 2026 |
| Galderma Laboratories, L.P. | 1 | gel | New drug applications (NDA) | May 22, 2026 |
| Glenmark Pharmaceuticals Inc., USA | 1 | gel | Generic drugs (ANDA) | November 8, 2019 |
| Mayne Pharma | 1 | gel | Authorized generics (NDA) | February 1, 2022 |
| Teva Pharmaceuticals, Inc. | 1 | gel | Generic drugs (ANDA) | November 28, 2022 |
| Viona Pharmaceuticals Inc | 1 | gel | Generic drugs (ANDA) | June 6, 2022 |
| Zydus Lifesciences Limited | 1 | gel | Generic drugs (ANDA) | June 6, 2022 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Gel | 15 | 100% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 13 | 86.7% |
| New drug applications (NDA) | 1 | 6.7% |
| Authorized generics (NDA) | 1 | 6.7% |
Pharmacologic classes
| Class | Products |
|---|---|
| Retinoid | 15 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.